Kabataş, SerdarCivelek, Erdinçİnci, ÇiğdemYalçınkaya, Ebru YılmazGünel, GülşenKır, GülayAlbayrak, EsraÖztürk, ErekAdaş, GökhanKaraöz, Erdal2020-08-302020-08-302018Kabatas, S., Civelek, E., Inci, C., Yalcinkaya, E. Y., Gunel, G., Kir, G., … Karaoz, E. (2018). Wharton’s Jelly-Derived Mesenchymal Stem Cell Transplantation in a Patient with Hypoxic-Ischemic Encephalopathy: A Pilot Study. CELL TRANSPLANTATION, 27(10), 1425–1433. https://doi.org/10.1177/09636897187866920963-68971555-3892https://doi.org/10.1177/0963689718786692https://hdl.handle.net/20.500.12713/741WOS: 000446855200002Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) have been introduced as a possible therapy in hypoxic-ischemic encephalopathy (HIE). We report a 16-year-old boy who was treated with WJ-MSCs in the course of HIE due to post-cardiopulmonary resuscitation. He received a long period of mechanical ventilation and tracheostomy with spastic quadriparesis. He underwent the intrathecal (1x10(6)/kg in 3 mL), intramuscular (1x10(6)/kg in 20 mL) and intravenous (1x10(6)/kg in 30 mL) administrations of WJ-MSCs for each application route (twice a month for 2 months). After stem cell infusions, progressive improvements were shown in his neurological examination, neuroradiological, and neurophysiological findings. To our best knowledge, this is a pioneer project to clinically study the neural repair effect of WJ-MSCs in a patient with HIE.eninfo:eu-repo/semantics/openAccessHypoxic-Ischemic EncephalopathyPost-Cardiopulmonary ResuscitationStem Cell TherapyWharton's JellyArticle27101425143330203688WOS:0004468552000022-s2.0-85054634600Q210.1177/0963689718786692Q2